Navigation Links
Biomarker associated with poor outcome in aggressive childhood cancer

Results from a new study identify a biomarker that may be useful for predicting the outcome of treatment for neuroblastoma, the most common cancer in young children. The research, published by Cell Press in the April 7th issue of the journal Cancer Cell, also provides new information about the molecular signals that are involved in the progression of this often devastating pediatric cancer.

Retinoic acid (RA) is a metabolite of Vitamin A that has important influences over the processes of growth and differentiation. RA mediates gene expression by interacting with retinoic acid receptors (RARs) that, in the presence of RA, switch from repressing target genes to activating them. Because many targets of RA induce differentiation or cell death, RA is used as a therapeutic agent in many cancers, including neuroblastoma.

"Many neuroblastoma patients exhibit aggressive tumors with poor clinical outcome," explains senior study author Dr. Rene Bernards from The Netherlands Cancer Institute. "While some of these aggressive tumors exhibit increased expression of the MYCN oncogene, little is known about the other genetic factors that control neuroblastoma progression." Dr. Bernards and colleagues performed a genome-wide RNA interference screen to search for additional components of the RA signaling pathway that might be linked to neuroblastoma.

The researchers identified ZNF423 as a critical cofactor of RA-induced differentiation. Reduced expression of ZNF423 was led to a growth advantage and resistance to RA differentiation in neuroblastoma cells while increased expression of ZNF423 led to growth inhibition and enhanced differentiation. The researchers went on to show that ZNF423 interacts with the RAR?/RXR? nuclear receptor that is necessary for activation in response to retinoids.

Importantly, low expression levels of ZNF423 were associated with poor disease outcome in neuroblastoma patients, suggesting that the gene might be useful as a prognostic biomarker. "Expression levels of ZNF423 could significantly affect responses to both endogenous and pharmacological concentrations of RA in cancer patients, which may in turn influence the outcome of neuroblastoma," offers Dr. Bernards. "Therefore, ZNF423 may be a useful biomarker for predicting responses to RA-based therapies, which are increasingly being used to treat neuroblastoma."


Contact: Cathleen Genova
Cell Press

Related medicine news :

1. Naturally fluorescent molecules may serve as cancer biomarker
2. Wayne State University Scientists ID New Biomarker for Prostate Cancer
3. Scientists ID New Biomarker for Prostate Cancer
4. Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimers disease
5. Dr. Arun Sreekumar lectures on new candidate biomarker at Annual EAU Congress
6. Biomarkers detected for Chikungunya fever
7. Biomarker predicts disease recurrence in colorectal cancer
8. Major study on DiagnoCures GCC biomarker published in Jama
9. Researchers ID Biomarker for Fatal Prostate Cancer
10. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
11. MDS Analytical Technologies Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
Breaking Medicine Technology: